Oxford Finance Closes Debt Facility with Pulmonx
Oxford Finance announced the closing of a $20 million senior secured term loan agreement with Pulmonx. Proceeds of the loan will be used to support the company’s U.S. clinical trial of its Zephyr Endobronchial Valve used for the treatment of emphysema and to expand its business worldwide.
“Emphysema is a serious disease affecting millions of people globally,” said Christopher A. Herr, managing director for Oxford Finance. “Pulmonx’s Zephyr Endobronchial Valve is a highly effective therapy for the treatment of this debilitating disease. Oxford is pleased to provide financing to support Pulmonx’s ongoing product development and marketing efforts, which will improve the lives of those suffering from emphysema.”
Redwood City, CA- and Neuchâtel, Switzerland-based Pulmonx is focused on developing and marketing minimally invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders.